Is BrainsWay Ltd. (NASDAQ:BWAY) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating BrainsWay Ltd. at current levels.
A profitable neurostim platform with 34% revenue growth, expanding label list, and a clinic install base that's starting to compound.
Where BWAY is headed
BrainsWay's installed base of Deep TMS systems is the asset most investors are still under-weighting. The company crossed into sustained GAAP profitability in 2025, runs 75% gross margins, and is growing the top line in the mid-thirties. That combination, in a medical device with FDA clearances across major depression, OCD, anxious depression, late-life depression, and smoking cessation, is rare. By the end of 2027 we expect BrainsWay to be doing roughly $90-100M in revenue at 18-20% operating margins, with a clinic install base materially larger than today and a consumables-like reimbursement tail that institutional buyers will eventually have to model as recurring.
Read the full Compass Direction on BWAY
The complete destination call, the overlooked angle, milestones, and bull, base, and bear price scenarios (around $14.43).
See the full BWAY analysisGet calls like this, free
Join the Alexandria e-letter for forward-looking verdicts, earnings intelligence, and the contrarian reads the crowd misses. Twice a week, no noise.
Free forever. Unsubscribe anytime. We never share your email.
Frequently asked questions
Is BrainsWay Ltd. (NASDAQ:BWAY) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating BrainsWay Ltd. at current levels. A profitable neurostim platform with 34% revenue growth, expanding label list, and a clinic install base that's starting to compound.
What is BWAY's Compass Score?
BrainsWay Ltd. scores 82/100 on Alexandria's Compass, placing it in the "True North" tier. Scores blend eight factors and update weekly.
What is the price target for BWAY?
Alexandria's full Compass Direction includes bull, base, and bear price scenarios with the valuation math behind each. Read the full breakdown on the BWAY page.
Compass verdicts are AI-generated, forward-looking editorial research from publicly available data, not investment advice or a recommendation regarding any security. Scores and verdicts update as the data changes.